Pulse Biosciences (PLSE) Stifel 2026 Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Stifel 2026 Healthcare Conference 2026 summary
12 Nov, 2026Technology and market opportunity
nsPFA uses pulse durations 1,000x shorter than microsecond PFA, with higher voltage amplitude; management says the distinct energy creates a different tissue mechanism of action.
Issued patents increased by 30, or more than 10%, this year; the platform has a 285-patent portfolio covering waveforms, methods and catheter design.
U.S. AF ablation market cited at $4B, with potential to approach $10B in the early 2030s; the market is projected to more than double over 5–7 years.
Feasibility workflow averaged 12 five-second applications; management cited faster procedures and potential for 2–3 additional cases per room daily, with $23,000 revenue per case for the service line.
Clinical evidence and regulatory plans
Paroxysmal AF feasibility results: 100% freedom from AF off drugs at 6 months, 96% at 12 months, and 90% freedom from all atrial arrhythmias at 12 months.
The pivotal paroxysmal AF IDE enrolled its final patient in October, in under 180 days; six-month data were expected by April, with a clinical module submission planned for early Q3 2027.
Management expects U.S. approval early in 2028, based on an estimated six-month FDA review; CE mark is expected in H2 2027.
A 100-patient, one-year follow-up update is targeted for Q1 at an AF conference; a persistent AF IDE filing is planned for Q4, with study start early the following year.
Pipeline and commercialization
A cardiac surgery IDE is enrolling patients with preoperative AF; additional European trials are planned to expand clinical experience.
Thyroid nodule treatment targets procedures that may preserve thyroid function; management described a 30–45-minute procedure with same-day discharge.
A next-generation catheter is planned to combine regional and focal ablation in one device; mapping integration has been demonstrated with Abbott EnSite X.
Management is preparing for a strategic partnership-led commercial approach while retaining the option to operate independently; manufacturing startup investment is beginning ahead of a potential 2028 launch at scale.
Cash and marketable securities totaled $189M at the prior quarter-end; management’s goal is to exit the year closer to $200M.
Latest events from Pulse Biosciences
- Pivotal AF enrollment finished early as cash reserves rose to $189.2M.PLSE
Q3 2026 - nsPFA technology delivers breakthrough efficacy in AFib and is poised for broad clinical adoption.PLSE
Canaccord Genuity's 46th Annual Growth Conference - nsPFA delivers superior ablation outcomes with robust IP and strong clinical and financial momentum.PLSE
Investor presentation - Pivotal trial enrollment accelerated, cash rose to $101.6M, and net loss reached $24.7M.PLSE
Q2 2026 - Directors and auditor ratified as company advances AFib trial and strengthens leadership.PLSE
AGM 2026 - Nanosecond PFA platform shows superior efficacy and is on track for early 2028 launch.PLSE
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Nanosecond PFA shows strong clinical promise in AFib, with accelerated pivotal study progress.PLSE
Bank of America Global Healthcare Conference 2026 - Accelerated pivotal trial progress, strong data, and $18.6M net loss with $0.4M revenue.PLSE
Q1 2026 - Advanced pivotal clinical programs in AF ablation with rising losses and modest initial revenue.PLSE
Q4 2025